A panoramic view of Gaogang district. [Photo/cmc.gov.cn]
A signing ceremony for 16 biopharmaceutical projects – with a combined investment of 4 billion yuan ($581.85 million) – was recently held in the Taizhou Medical High-tech Zone, also known as Gaogang district, located in Taizhou city, in East China's Jiangsu province.
The projects cover such fields as antibodies, vaccines, medical devices, chemicals and special medical food – with large investment volumes, advanced technologies and broad market prospects.
One appealing one, aiming to produce anti superbug products, is operated by Kaifeinuo (Taizhou) Biotechnology Co Ltd. The project is being led by an academician from the American Academy of Microbiology named Li Jian and will focus on innovative research and commercialization of new drugs and medical devices related to polymyxin.
In terms of special medical food, a food production plant being invested in by Methuselah Medical Technology (Shanghai) Co Ltd will be engaged in producing a "healing elements" range of products – designed to meet the nutritional needs of those undergoing surgical procedures and people with specific medical conditions.
A herpes zoster vaccine production plant costing 1 billion yuan is the largest investment project this time. Once the product is launched, it is expected to fill a gap in its field in China and generate annual output value of 2 billion yuan.